10x Genomics Seats A Stanford Immunologist And Glaukos's Operating Chief, With A New Audit Chair
Ansuman Satpathy and Joseph Gilliam joined the board as Class III directors, and Gilliam now chairs the audit committee.
10x Genomics, which makes instruments and software for studying biology at the single-cell level, added two directors on Wednesday: Stanford immunologist Ansuman Satpathy and Glaukos President and Chief Operating Officer Joseph Gilliam. Gilliam was named chair of the audit committee on Friday, according to an 8-K filed Monday.
Two seats, both through 2028
The board acted on the recommendation of its nominating and corporate governance committee. Both men took Class III seats effective immediately, with terms running to the 2028 annual meeting of stockholders.
Gilliam's audit chair role, effective October 30, carries an annual retainer of $25,000, prorated as necessary.
A scientist and a former banker
Satpathy is an associate professor of pathology and immunology at Stanford, a venture partner at Wing Venture Capital, and a co-founder of four private life sciences companies: Immunai, Cartography Biosciences, Santa Ana Bio and Arpelos Biosciences. He also directs the Stanford Center for Immunotherapy Design.
Gilliam has been Glaukos's president and chief operating officer since April 2022, after serving as its chief financial officer from May 2017. Before that he was a managing director in healthcare investment banking at JPMorgan Chase, and he began his career at PricewaterhouseCoopers. He sits on the board of Caris Life Sciences, where he serves on the audit and compensation committees.
The company said Satpathy brings scientific training and genomics and immunology expertise. It said Gilliam brings financial leadership experience at a publicly traded medical technology company and audit committee experience.
Satpathy's advisory deal ended first
Satpathy had advised 10x as a scientist under an agreement signed December 13, 2024, for which the company granted him 10,000 restricted stock units. The agreement was terminated in October 2026, before his board appointment.
10x, whose Chromium, Visium and Xenium platforms serve academic, government and biopharmaceutical researchers, reported 2025 revenue of $642.8 million.
Pay and grant dates
Each director receives a $60,000 annual cash retainer under the company's non-employee director pay policy. Each also gets a one-time restricted stock unit grant with a $400,000 target value, due November 30, 2026, plus an annual grant targeted at $215,000.
The annual grant is made on the date of the annual meeting of stockholders.
The first annual grants for Satpathy and Gilliam will come at the company's next annual meeting; the $400,000 awards land November 30.
Sources
- 8-K Filing — 10x Genomics, Inc. (TXG) — SEC EDGAR